文献速递淋巴瘤

mTOR抑制增强PI3Kβ/δ阻断对弥漫大B细胞淋巴瘤的抗淋巴瘤效应

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2022-11-09

本研究探讨特异性PI3Kβ/δ抑制剂AZD8186在弥漫大B细胞淋巴瘤(DLBCL)模型中的抗淋巴瘤疗效。部分活化B细胞样(ABC)和生发中心B细胞样(GCB)DLBCL模型对AZD8186敏感,耐药模型出现PI3K/AKT/mTOR通路反馈激活。AZD8186联合mTOR抑制剂AZD2014克服耐药,在细胞系和患者来源异种移植小鼠模型中完全阻止淋巴瘤细胞生长。

要点

  • 部分ABC和GCB DLBCL模型对PI3Kβ/δ抑制剂AZD8186敏感。
  • AZD8186耐药模型存在PI3K/AKT/mTOR通路反馈激活。
  • AZD8186联合AZD2014在体内完全阻止淋巴瘤细胞生长。

核心结论

  • 部分DLBCL依赖PI3Kβ/δ信号,PI3Kβ亚型在DLBCL生存中具有此前未被认识的作用。
  • 联合靶向PI3Kβ/δ和mTOR在所有主要DLBCL亚型中有效,支持在临床试验中评估该策略。

研究设计与样本

  • 研究使用特异性PI3Kβ/δ抑制剂AZD8186,在活化的B细胞样(ABC)和生发中心B细胞样(GCB)DLBCL模型中进行体外和体内研究。
  • 体内研究采用细胞系来源和患者来源的异种移植小鼠模型。

主要发现

  • 在分子水平,PI3Kβ/δ抑制降低促生存的NF-κB和AP-1活性,或导致致癌转录因子MYC下调。
  • 在AZD8186耐药模型中,检测到PI3Kβ/δ抑制后PI3K/AKT/mTOR通路反馈激活,限制了AZD8186疗效。
  • AZD8186联合mTOR抑制剂AZD2014克服了对PI3Kβ/δ抑制的耐药,在体内细胞系和患者来源异种移植小鼠模型中完全阻止淋巴瘤细胞生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease that exhibits constitutive activation of phosphoinositide 3-kinase (PI3K) driven by chronic B-cell receptor signaling or PTEN deficiency. Since pan-PI3K inhibitors cause severe side effects, we investigated the anti-lymphoma efficacy of the specific PI3Kβ/δ inhibitor AZD8186. We identified a subset of DLBCL models within activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL that were sensitive to AZD8186 treatment. On the molecular level, PI3Kβ/δ inhibition decreased the pro-survival NF-κB and AP-1 activity or led to downregulation of the oncogenic transcription factor MYC. In AZD8186-resistant models, we detected a feedback activation of the PI3K/AKT/mTOR pathway following PI3Kβ/δ inhibition, which limited AZD8186 efficacy. The combined treatment with AZD8186 and the mTOR inhibitor AZD2014 overcame resistance to PI3Kβ/δ inhibition and completely prevented outgrowth of lymphoma cells in vivo in cell line- and patient-derived xenograft mouse models. Collectively, our study reveals that subsets of DLBCLs are addicted to PI3Kβ/δ signaling and thus identifies a previously unappreciated role of the PI3Kβ isoform in DLBCL survival. Furthermore, our data demonstrate that combined targeting of PI3Kβ/δ and mTOR is effective in all major DLBCL subtypes supporting the evaluation of this strategy in a clinical trial setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Xu W, Berning P, Erdmann T, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 2022. PMID: 36352190. doi:10.1038/s41375-022-01749-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。